On Apr. 17, 2020, Celdara Medical announced that it had entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases and The Geneva Foundation.

This collaboration focused on the development of a therapeutic antibody cocktail candidate for the treatment of Sudan virus, using established animal models to test efficacy against viral infection. There are currently no available therapeutic countermeasures as a part of the U.S. Strategic National Stockpile for Sudan virus.